Equities

Aadi Bioscience Inc

Aadi Bioscience Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.13
  • Today's Change0.025 / 1.19%
  • Shares traded16.00
  • 1 Year change-54.30%
  • Beta0.6931
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing precision therapies for cancers with alterations in the mammalian target of rapamycin (mTOR) pathway, a regulator of cell growth and cancer progression. Its lead drug product, FYARRO, is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is a form of sirolimus bound to albumin. Sirolimus is a potent inhibitor of the mTOR biological pathway and inhibits downstream signaling from mTOR, which can promote tumor growth. FYARRO is composed of nanoparticles of sirolimus bound to human albumin with an average size less than 100 nanometers. It has also initiated a tumor-agnostic Phase II study (PRECISION 1) of FYARRO in patients with Tuberous Sclerosis Complex 1 and 2 (TSC1 and TSC2) alterations.

  • Revenue in USD (TTM)25.07m
  • Net income in USD-61.69m
  • Incorporated2007
  • Employees53.00
  • Location
    Aadi Bioscience Inc17383 Sunset Avenue, Suite A250PACIFIC PALISADES 90272United StatesUSA
  • Phone+1 (424) 473-8055
  • Fax+1 (302) 655-5049
  • Websitehttps://aadibio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Verrica Pharmaceuticals Inc9.21m-84.99m35.41m100.00------3.84-1.83-1.830.1979-0.74670.14161.674.6792,100.00-130.68-55.75-174.03-78.3374.08---922.81-754.941.22-10.163.82---43.27---173.59--5.65--
Dare Bioscience Inc2.84m-7.20m36.17m23.00--13.31--12.74-1.07-1.070.35790.31260.1213--3.85123,462.20-30.76-109.51-191.39-246.260.8477---253.60-1,104.55----0.00---71.92--2.54--121.37--
Lexaria Bioscience Corp411.01k-4.85m41.19m5.00--3.69--100.21-0.4455-0.44550.04080.64030.0539--2.1682,202.00-63.85-95.67-65.93-96.5898.8376.98-1,185.15-1,612.76---64.960.00---11.43-12.198.31------
Eyenovia Inc31.41k-37.28m42.25m57.00------1,345.00-0.7897-0.78970.0007-0.04250.0013--0.0418551.05-154.24-80.31-262.28-117.70-1,489.11---118,693.60-680.950.267-40.921.20------2.68--152.20--
Earth Science Tech Inc20.30m1.98m43.27m32.0021.9113.6720.172.130.00640.00640.06580.01035.4036.44--634,456.9052.57-37.9877.89--69.4063.879.74-15.481.243.570.0261--24,526.3773.03322.25------
CEL-SCI Corp0.00-29.10m44.77m43.00--4.66-----0.5806-0.58060.000.15620.00-------100.88-70.19-124.78-78.31-------15,434.150.1793-36.790.5517------13.99--223.59--
Fortress Biotech Inc82.62m-49.54m47.13m186.00--2.16--0.5705-3.71-3.716.050.79150.50632.366.07444,215.10-65.90-52.50-113.69-99.4668.7763.17-130.17-236.941.24-13.401.26--11.5825.7527.42---9.37--
Incannex Healthcare Inc12.00k-18.46m48.87m9.00--3.92--4,072.55-1.14-1.140.00070.70670.0003--0.00241,333.33-48.51-130.12-54.36-148.24-----153,833.30-3,421.98----0.00----61.0362.18--73.79--
United-Guardian, Inc.12.31m3.25m49.57m25.0015.274.0914.804.030.70650.70652.682.640.95754.127.65492,387.2025.2529.8428.6734.3950.6655.3126.3728.796.99--0.0097.37-14.28-4.140.4616-9.9217.19-19.73
SCYNEXIS Inc8.57m-36.44m49.59m29.00--0.8493--5.79-0.756-0.7560.1771.540.0692--3.61295,379.30-29.44-30.02-35.54-36.35-71.42---425.41-86.76----0.1843--2,652.72252.64206.74------
Odonate Inc0.00-102.07m49.87m137.00--1,839.01-----13.59-13.590.009.270.00----0.00-66.98-58.36-83.00-65.14------------0.00-------12.99------
Immix Biopharma Inc0.00-19.02m51.06m14.00--2.14-----0.8411-0.84110.000.8710.00----0.00-86.64---100.82--------------0.00-------87.44------
Aadi Bioscience Inc25.07m-61.69m52.31m53.00--0.7595--2.09-2.29-2.290.92852.800.22250.6964.09281,685.40-54.75-50.25-65.27-56.1587.39---246.06-473.974.54--0.00--60.063.85-8.68--153.54--
BGM Group Ltd29.87m-7.86m52.83m298.00--1.20--1.77-1.10-1.104.186.070.52373.7325.96100,236.40-14.432.71-17.013.862.9211.66-27.562.726.06-0.75270.0026.11-28.35-1.60-822.64--12.86--
Data as of Nov 08 2024. Currency figures normalised to Aadi Bioscience Inc's reporting currency: US Dollar USD

Institutional shareholders

45.95%Per cent of shares held by top holders
HolderShares% Held
Avoro Capital Advisor LLCas of 30 Jun 20242.85m11.58%
BML Capital Management LLCas of 30 Sep 20242.00m8.13%
Acuta Capital Partners LLCas of 30 Jun 20241.85m7.51%
EcoR1 Capital, LLCas of 23 Aug 20241.85m7.50%
The Vanguard Group, Inc.as of 30 Jun 2024760.65k3.09%
Citadel Advisors LLCas of 30 Jun 2024486.41k1.98%
Renaissance Technologies LLCas of 30 Jun 2024439.22k1.78%
Acuitas Investments LLCas of 30 Sep 2024438.76k1.78%
Soleus Capital Management LP (Investment Management)as of 30 Jun 2024333.23k1.35%
BlackRock Fund Advisorsas of 30 Jun 2024307.15k1.25%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.